Trials / Conditions / Waldenström Macroglobulinemia (WM)
Waldenström Macroglobulinemia (WM)
5 registered clinical trials studyying Waldenström Macroglobulinemia (WM) — 4 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Recruiting | Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma NCT07249905 | ModeX Therapeutics, An OPKO Health Company | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Do NCT07259122 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Enrolling By Invitation | Watch and Wait or Worry and Wait in Indolent Lymphoma NCT07173790 | Seoul National University Hospital | — |
| Not Yet Recruiting | Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobuline NCT07169565 | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 |
| Active Not Recruiting | An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia NCT02180724 | Acerta Pharma BV | Phase 2 |